Alvotech

Alvotech Liabilities

The The Liabilities of Alvotech (ALVO) as of Oct 16, 2026 is 1.77 B USD. In the previous year, The Liabilities was 1.63 B USD — a change of 8.41% (higher).

Liabilities

1.77 BUSD

YoY

8.41%

Last updated:

In 2025, Alvotech's total liabilities amounted to 1.77 B USD, a 8.41% difference from the 1.63 B USD total liabilities in the previous year.

The Alvotech Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2020
1.34 B USD
Jan 1, 2021
733.59 M USD
Jan 1, 2022
1.39 B USD
Jan 1, 2023
1.88 B USD
Jan 1, 2024
1.63 B USD
Jan 1, 2025
1.77 B USD
The Alvotech Liabilities history
YEARLiabilitiesYoY
1.77 BUSD+8.41%
1.63 BUSD-13.20%
1.88 BUSD+35.16%
1.39 BUSD+89.87%
733.59 MUSD-45.32%
1.34 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alvotech Stock analysis

What does Alvotech do? Alvotech SA, listed on the stock market with ticker ALVO and ISIN LU2458332611, is a biotechnology company headquartered in Luxembourg. The company, which went public in November 2020, employs approximately 1,500 people. Alvotech focuses on the development and manufacturing of biosimilar medicines, aiming to provide affordable treatment options globally. Its pipeline includes eight biosimilar candidates targeting various therapeutic areas such as inflammatory diseases, oncology, and ophthalmology. Specific products in development include AVT02, a biosimilar to Humira (adalimumab), and AVT04, a biosimilar candidate to Stelara (ustekinumab). The company has established strategic commercial partnerships to expand its global reach, leveraging expertise in key markets including the United States, Europe, Japan, China, and regions across South America, Africa, and the Middle East. Alvotech's approach emphasizes the creation of high-quality biosimilars to address unmet medical needs in multiple disease areas. The company operates within the healthcare sector, specifically in biotechnology, and has positioned itself as a key player in the biosimilars market. With a focus on monoclonal antibodies, Alvotech aims to deliver innovative therapies that are both effective and cost-efficient for patients worldwide. Alvotech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Alvotech's Liabilities

Alvotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Alvotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Alvotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Alvotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Alvotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Alvotech stock

The Liabilities of Alvotech is 1.77 B USD in 2025.

The Liabilities of Alvotech changed from 1.63 B USD to 1.77 B USD, representing a 8.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Alvotech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Alvotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alvotech

All Key Metrics — Alvotech